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There is a known relationship between serum alanine aminotransferase (ALT) and obesity in humans, but the mechanism(s) are
not clarified. This study investigated the associations between serum ALT and body composition in an overweight and obese
population. The results are based on data from a previous randomized controlled trial treating obesity with vitamin D3. A
sample of 448 overweight and obese individuals underwent dual-energy X-ray absorptiometry (DEXA) and measured serum
ALT along with supplementary blood samples at study baseline. Body fat mass and lean mass indexes were calculated by
dividing total body fat/lean weight (kg) by body height squared (kg/m2). ALT correlated with body mass index (BMI) in men
but not women (r = 0 33, P < 0 0001 vs. r = 0 06, P = 0 29). In men, serum ALT correlated positively with fat mass index
(r = 0 23, P = 0 004) and lean mass index (r = 0 32, P < 0 0001). In women, ALT correlated with lean mass index (r = 0 13, P =
0 031) but not fat mass index (r = 0 003, P = 0 96). In a multivariate model adjusted for age and fat mass index, a 1-unit increase
in lean mass index associated with a 0.37U/L higher ALT in the male subgroup (95% CI 0.024 to 0.040, P < 0 0001). In
conclusion, serum ALT was associated with body fat mass index in men and with lean mass index in men and women in an
overweight and obese population. The findings also demonstrate a gender difference in the role of fat.
1. Introduction
Alanine transaminase (ALT) is associated with obesity [1, 2],
cardiovascular disease (CVD), and CVD-related mortality
[3–5]. Clinical and population studies have related ALT with
insulin resistance, metabolic syndrome, and type 2 diabetes
[6–8]. Obesity is reported to be a major risk factor to develop
nonalcoholic fatty liver disease (NAFLD), a common liver
disease defined as ≥5% fat liver [9], and an important
mechanism behind the relationship between ALT and risk
of CVD [10, 11]. Hepatic accumulation of lipids occurs ini-
tially while inflammation and oxidative stress in response
to increased lipid activity are further reaction characteristic
for the disease [12, 13].
A Korean population study showed a higher risk of
elevated ALT by increasing degree of BMI [14]. Odds ratio
for elevated ALT in obese subjects was 5.0 in men and 3.9
in women [14]. In studies from the United States
confirming a positive relationship between ALT and BMI,
the strongest association was found for waist-to-hip ratio
[15] and trunk fat using dual-energy X-ray absorptiometry
(DEXA) to measure body composition, indicating central
adiposity to be an important obesity-related determinant of
elevated ALT [16]. ALT was also associated with trunk lean
mass in both sexes [16].
Little is known about the muscular role of ALT in
general, and obesity in particular, but the parallel increase
and the following recovery of ALT released to the circulation
in response to muscle injury, seizure, and inflammation
may reflect some underlying mechanisms [17, 18]. There
is emerging evidence that loss of muscle mass (sarcopenia)
plays a role in the complex pathophysiology of NAFLD
[19]. One link between them is insulin resistance, which
is associated with muscle loss [20]. Furthermore, in a
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retrospective cohort, age-related reduction in skeletal muscle
mass and increase in fat mass over time were associated with
incidents of NAFLD, although only in nonobese subjects
[21]. The relative contribution of fat mass and lean mass to
the relationship with ALT and how it integrates with obesity
in presumptive healthy obese individuals is necessary supple-
mentary knowledge to obtain. The study purpose was to
investigate the relationship between ALT and body composi-
tion in an overweight and obese population.
2. Material and Methods
2.1. Study Participants. Using data from a randomized
controlled trial (RCT) treating obesity with vitamin D3
[22], the present study was designed with the following
criteria: males and females 21-70 years of age with BMI
between 28.0 and 47.0 kg/m2 were accepted for inclusion.
Diabetes, history of heart infarction, angina pectoris and
stroke, weight loss > 10 kg last six months, use of antidepres-
sants and drugs with weight-reducing properties, participa-
tion in weight loss programs, pregnant and lactating
women, women with pregnancy plans next 12 months,
women < 50 years without use of contraceptives, males with
serum creatinine > 129 μmol/L, and females with serum
creatinine > 104 μmol/L were the exclusion criteria. The oral
glucose tolerance test was performed in all participants to
detect unrecognized diabetes. All participants recruited from
this general population were Caucasians. No systemic disor-
ders including malignancies, alcoholism, hepatitis or other
hepatic disorders, or use of hepatotoxic medication were
identified in any subjects. The participants were either
recruited via newspaper advertisement or from the medical
outpatient clinic at the University Hospital of North Norway.
Written consent was obtained from all, and the Norwegian
Committee for Medical and Health Research Ethics (REC)
approved the study. The study was conducted in accordance
with the Helsinki Declaration.
2.2. Measurements. Only baseline data were used. Standard-
ized measurements of height and weight were performed
with light clothing without shoes, and body mass index
(BMI) was calculated as weight (kg) divided by height
squared (m2). Body composition measurements with DEXA
(GE Lunar Prodigy, LUNAR Corporation, Madison, WI,
USA) were performed, and body fat index was calculated
by dividing total body fat weight (kg) by body height
squared (m2). The same was done for lean mass. Physical
activity, a potential confounder, was calculated by the short
version (7 days) of the International Physical Activity Ques-
tionnaire (IPAC) [23]. Vigorous, moderate, and walking
activities are transformed to units of metabolic equivalents
(MET)-min/week, where METs are multiples of the resting
metabolic rates.
Serum ALT was analyzed consecutively within 6 hours
after the phlebotomies in an automated clinical chemistry
analyzer (Modular P, Roche) by photometry, using an enzy-
matic method (CK-NAC, Roche Diagnostics, Mannheim,
Germany). Reference limits for serum ALT were 10-70U/L
(men) and 10-45U/L (women). The lower detection limit
of ALT assay was 5.0U/L. The analytical variation (Vka) of
ALT is 4.9%. The standard cut-off limits for ALT and AST
used in the hospital are developed by the Nordic Reference
Interval Project (NORIP) [24]. AST/ALT ≥ 2 and ≥3 were
calculated to detect participants at risk of alcoholic liver
disease [25]. Gamma-glutamyl transpeptidase (GGT) was
measured with references 10-80U/L (men 18-39 years), 15-
115U/L (men ≥ 40 years), 10-45U/L (women 18-39 years),
and 10-75U/L (women ≥ 40 years) with 3.2% Vka. Nonfast-
ing S-glucose and glycosylated hemoglobin (HbA1C) in
EDTA whole blood based on an immune turbidometric assay
(UNIMATES, F. Hoffmann-La Roche AG) were obtained.
The HbA1C% was calculated from the HbA1C/Hb ratio.
Serum total cholesterol was analyzed by an enzymatic color-
imetric method using a commercially available kit (CHOD-
PAP, Boehringer-Mannheim, Mannheim, Germany). All
analyses were done at the Department of Clinical Biochemis-
try, University Hospital of North Norway.
2.3. Statistical Analysis. The statistical analysis was per-
formed by SPSS software version 25 (SPSS INC., Chicago,
Illinois, USA). Distributions of the data were reviewed by
visual inspection of histograms and by calculation of kurtosis
and skewness. The histograms showed right-sided skewness
in all endpoint variables. Serum ALT (skewness 2.7, kurtosis
4.0) and serumAST (skewness 4.2, kurtosis 37.3) confirmed a
non-Gaussian distribution of the data. Log-transformed data
were normal-distributed and therefore used in the analyses.
The analyses were performed sex-stratified since levels of
ALT and components of body composition are different in
men and women. Descriptive data are presented as mean
± standard deviations (SD) or numbers and frequencies.
Two-sided Student’s t-test was used to calculate differences
between means and ANOVA used to compare body compo-
sition with quartiles of ALT (analyses of trends). The χ2 test
was used to compare frequencies of data within groups
(dichotomous data). By multiple regression analysis, possi-
ble confounders were tested and adjusted for with ALT as
dependent variables, and variables that significantly corre-
lated with ALT were included in the regression model as
independent variables. Regression coefficients (ß) with 95%
confidence interval (CI) were calculated. The level of signif-
icance was set at ≥5%.
3. Results
Clinical variables of the study population are listed in Table 1.
A majority of the participants were obese (BMI ≥ 30 kg/m2),
while about 10% of both sexes were overweighed
(25 ≥ BMI < 30 kg/m2) (Table 1). ALT was associated with
BMI in men but not in women (Table 2), and BMI was
significantly associated with ALT quartiles in men
(Table 3). In contrast to women, ALT correlated positively
with fat mass index in men and with lean mass indexes in
both sexes (Table 2, Figures 1–4). ALT was significantly cor-
related with serum glucose, HbA1C, and cholesterol in
women but not in men (Table 2). The highest ALT value
was 120U/L (woman) and the highest AST was 137U/L
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Table 1: Clinical characteristics of the subjects. Numbers (%) or mean (SD) is presented.
Variables Total group (n = 448) Men (n = 157) Women (n = 291) P
Age (years) 47.5 (11.4) 47.8 (10.8) 47.4 (11.8) 0.15
Use of antihypertensive drugs 93 (20.8) 33 (21.0) 60 (20.6) 1.0
Statin use 43 (9.6) 12 (7.6) 31 (10.7) 1.0
NSAID 74 (16.5) 27 (17.2) 47 (16.2) 1.0
H2-blocking drugs 14 (3.1) 3 (1.9) 11 (3.8) 1.0
Antidepressants 25 (5.6) 10 (6.4) 15 (5.2) 0.52
Height (cm) 169.3 (8.9) 178.3 (6.1) 164.5 (6.0) 0.76
Weight (kg) 99.3 (14.2) 109.2 (11.2) 94.0 (11.7) 0.020
BMI (kg/m2) 34.6 (3.9) 34.3 (3.6) 34.7 (4.1) 0.15
Obesity (BMI ≥ 30 kg/m2) 406 (90.6) 141 (89.8) 265 (91.1) 0.73
Overweight (25 ≥ BMI < 30 kg/m2) 42 (9.4) 16 (10.2) 26 (8.9) 1.0
Fat mass (kg) 40.6 (8.3) 36.7 (8.4) 42.6 (7.6) 0.018
Lean mass (kg) 54.2 (11.7) 67.5 (7.4) 47.1 (5.9) 0.027
Fat mass index (kg/m2) 14.3 (3.4) 11.5 (2.6) 15.8 (2.8) <0.0001
Lean mass index (kg/m2) 18.7 (2.6) 21.2 (1.9) 17.4 (1.9) <0.0001
ALT (U/L)∗ 31.2 (17.5) 38.5 (15.9) 27.3 (17.1) <0.0001
High ALT∗∗ 38 (8.5) 4 (2.5) 34 (11.7) 0.001
AST (U/L)∗ 25.7 (10.0) 29.0 (8.7) 24.0 (10.3) 0.72
High AST∗∗ 37 (8.3) 12 (7.6) 25 (8.6) 0.86
GGT (U/L) 32.0 (38.8) 37.2 (39.2) 27.4 (37.9) <0.0001
Creatine kinase (U/L)∗ 121.6 (120.3) 178.5 (180.7) 91.0 (46.3) <0.0001
S-glucose (mmol/L) 5.35 (0.64) 5.47 (0.59) 5.27 (0.64) 0.92
S-HbA1c (%) 5.66 (0.38) 5.67 (0.42) 5.65 (0.36) 0.14
Hs-CRP (mg/dL)∗ 4.08 (4.87) 3.30 (4.71) 4.45 (4.82) 0.08
S-total cholesterol (mmol/L) 5.37 (1.00) 5.40 (0.89) 5.36 (1.06) 0.022
Physical activity score (MET-min/week)∗ 3207.0 (3836.0) 3046.7 (4273.2) 3297.8 (3587.4) <0.0001
BMI: body mass index; ALT: alanine transaminase; AST: aspartate aminotransferase; GGT: gamma-glutamyl transpeptidase; Hs-CRP: high sensitive C-reactive
protein; MET: metabolic equivalent; NSAID: nonsteroid antiflogistic drugs. ∗Analyzed log-transformed. ∗∗Above reference limit.
Table 2: Correlations between ALT∗, body composition, and potential confounders.
ALT (U/L)
Men (n = 157)
ALT (U/L)
Women (n = 291)
r P r P
Age (years) -0.19 0.017 0.23 <0.0001
BMI (kg/m2) 0.33 <0.0001 0.006 0.29
Fat mass index (kg/m2) 0.23 0.004 0.003 0.96
Lean mass index (kg/m2) 0.32 <0.0001 0.13 0.031
Creatine kinase (U/L)∗ 0.15 0.07 0.06 0.35
S-glucose (mmol/L) 0.09 0.27 0.23 <0.0001
S-HbA1C (%) 0.11 0.18 0.19 0.001
Hs-CRP (mg/dL)∗ 0.06 0.44 -0.01 0.84
S-total-cholesterol (mmol/L) 0.02 0.86 0.16 0.005
Physical activity score (MET-min/week)∗ -0.09 0.31 -0.02 0.80
BMI: body mass index; ALT: alanine transaminase; Hs-CRP: high sensitive C-reactive protein; MET: metabolic equivalent. ∗Analyzed log-transformed.
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(woman). Nine participants (3 men and 6 women) had
AST/ALT index ≥ 2 and 2 women had AST/ALT index ≥ 3.
Fat mass and lean mass indexes increased significantly
with increasing quartiles of serum ALT in men in a trend
analysis using ANOVA (Table 4). In contrast, lean mass
but not fat mass indexes increased significantly from quar-
tiles 1 to 4 of serum ALT in women (Table 3). Lean mass
index was inversely and independently associated with serum
ALT when adjusted for covariates in men (Table 4). Further-
more, a 1-unit increase in lean mass was associated with
0.37U/L higher serum ALT when adjusted for age and fat
mass index (Table 4). This association was independent
and significant also when replacing body composition
variables with BMI (data not shown).
4. Discussion
ALT was log-linearly and positively associated with fat mass
index and lean mass index in men and with lean mass index
in women in an obese cohort. After adjusting for obesity-
related variables, body lean mass index remained indepen-
dently associated with ALT in the male subgroup. ALT
may hypothetically play a favourable role in the adipose pro-
cess, but the fat mass component of body composition may
act differently in women.
Although ALT is mainly located in the liver, alanine
synthesis also occurs in muscle tissue [26, 27]. A parallel
increase and recovery after muscular strain in both ALT
and in the energy reactive muscle enzyme creatine kinase
Table 3: Fat mass index, lean mass index, and confounders in quartiles of serum ALT.
ALT∗ quartiles
Q1 Q2 Q3 Q4 P for trend
Q-intervals (U/L) (men) ≤1.42 1.43-1.54 1.55-1.66 ≥1.67
N = 157 37 40 38 42
Age (years) 51.1 (11.9) 48.8 (11.8) 45.6 (9.6) 45.9 (10.0) 0.09
BMI (kg/m2) 32.7 (3.3) 33.8 (3.5) 34.7 (3.0) 36.0 (3.5) <0.0001
Fat mass index (kg/m2) 10.4 (2.2) 11.7 (2.6) 11.6 (2.6) 12.3 (2.4) 0.008
Lean mass index (kg/m2) 20.7 (1.7) 20.7 (1.8) 21.5 (1.5) 22.2 (2.0) <0.0001
Q-intervals (U/L) (women) ≤1.22 1.23-1.33 1.34-1.48 ≥1.49
N = 291 69 72 71 79
Age (years) 42.4 (12.1) 45.7 (12.0) 50.6 (12.4) 51.0 (9.8) <0.0001
BMI (kg/m2) 33.9 (3.8) 34.6 (3.9) 35.7 (4.3) 34.7 (4.2) 0.62
Fat mass index (kg/m2) 15.5 (2.7) 15.5 (2.9) 16.6 (2.9) 15.5 (2.7) 0.10
Lean mass index (kg/m2) 16.9 (1.7) 17.4 (1.6) 17.5 (2.1) 17.7 (1.9) 0.078
S-glucose (mmol/L) 5.06 (0.60) 5.19 (0.55) 5.45 (0.71) 5.37 (0.60) 0.001
S-HbA1C (%) 5.54 (0.34) 5.61 (0.36) 5.76 (0.36) 5.67 (0.34) 0.003
S-total-cholesterol (mmol/L) 5.02 (0.94) 5.18 (1.11) 5.63 (1.04) 5.54 (1.03) 0.001
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Figure 1: Correlation between alanine aminotransferase (ALT) and fat mass in 157 obese men (r = 0 23, P = 0 004).
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(CK) are reported [18]. In patients with rhabdomyolyses
(CK ≥ 1000U/L), 75% had abnormal ALT, which confirms
its muscular involvement [28]. In contrast to ALT, CK was
not associated with muscle mass in obese subjects measured
at rest indicating different muscular relationships between
them [29]. Whether ALT plays a positive or negative role,
or both, in the CVD processes is discussed in the literature.
Sarcopenia (age-related loss of muscle mass and strength) is
an area of research where the ALT-muscular relationship
has been questioned. Both adiposity and sarcopenia share
in common an increased risk of NAFLD, and both have been
associated with ALT and insulin resistance [14, 21, 30].
Furthermore, increased ALT may predict reduced insulin
sensitivity and diabetes [6, 7]. The mechanisms are complex
and incompletely understood, but the relationship between
ALT and muscle mass as well as insulin resistance may be
mediated by inflammation. ALT was associated with low-
graded inflammation (CRP) in 1483 middle-aged Japanese
men, and proinflammatory cytokines may exert a negative
(catabolic) muscular effect [31, 32]. Additionally, insulin
resistance in skeletal muscle may be produced by inflamma-
tory activity such as tumor necrosis factor alpha and comple-
ment 3 [33, 34]. It is previously known that obesity-related
inflammation stimulate progression of NAFLD and develop-
ment of insulin resistance [12, 13]. Lack of relationship
between ALT and CRP in the present study does not exclude
the influence of inflammatory metabolites, however.
The Korean sarcopenia obesity study reported recently a
5.2-time increased risk of NAFLD in the sarcopene obese
group compared to nonobese [30]. An inverse correlation
between ALT and skeletal muscle mass index as well as total
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Figure 3: Correlation between alanine aminotransferase (ALT) and lean mass in 157 obese men (r = 0 32, P < 0 0001).
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components of metabolic syndrome, and LDL-cholesterol
were reported [30]. Moreover, ALT was inversely associated
with sarcopenia, CVD, and overall mortality in 765 elderly
subjects analyzed in prospective population-based data
[35]. ALT correlated with appendicular lean mass, trunk lean
mass, and total lean mass but not fat mass in a group of 174
healthy young athletic women [36]. A US population-based
study measuring body mass with DEXA showed an associa-
tion between lower ALT and mortality risk [37]. Lower
values of appendicular lean mass were found in the three
lowest ALT centiles when adjusted for total body fat mass,
which could possibly explain the lower mortality rate in those
with low ALT values [37]. In line with this, ALT was inversely
and linearly associated with CVD risk in a 10.5-year follow-
up study that included 6899 participants and 729 CVD
events [38]. We did not measure partial body composition
such as appendicular lean mass, neither was muscular power
examined. Highly significant associations between ALT and
total body lean mass in the present study in otherwise healthy
obese individuals make that explanation less likely. ALT, by
its muscular connection, may hypothetically play a beneficial
role in the adipose process. The interrelationships between
ALT, NAFLD, lean mass, and inflammation should be
targeted in future studies.
ALT is connected with adiposity and CVD risk factors
[39]. A positive association between ALT and trunk fat inde-
pendent of trunk and extremity lean mass was found in one
study [16], while central adiposity along with generalized
adiposity is reported by others [5]. Furthermore, ALT was
not elevated in otherwise healthy obese people in a clinical
study with limited number of participants contrasting our
results [40]. This corresponds approximately with the
relatively small subgroup with elevated ALT frequency
(about 8%) found in the present study. Overall, relationships
between ALT and CVD risk are complex [41, 42]. Addition-
ally, how lean mass and fat mass act in the atherosclerotic
process is not clear. Lean mass was independently associated
with carotid media thickness in 421 obese subjects [43] and
was associated with carotid lumen diameter in another study
[44]. On the other hand, lean mass predicted a better cardiac
function in a 10-year follow-up study of obese subjects
indicating a protective CVD effect [45].
As found in the present study, ALT is reported to be
higher in males than females [46, 47]. Whether this is due
to different fat vs. lean mass contribution, the effect of sex
hormones or other mechanisms is not known. The positive
relationship between ALT and the muscular component
relative to fat in the female group of the present obese body
composition sample illustrates the complexity of body
composition and its connection with ALT. Whether ALT
may play a beneficial role in the adipose female process is
an open question. Thus, ALT predicted coronary heart dis-
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Figure 4: Correlation between alanine aminotransferase (ALT) and lean mass in 291 obese women (r = 0 13, P = 0 031).
Table 4: Associations between ALT∗ (dependent variable) and
independent variables in overweight and obese men and women.
ALT (U/L) as dependent variable
ß∗∗ 95% CI P
Men (n = 157)
Age (years) 0.12 0.001 to 0.004 0.008
Fat mass index (kg/m2) 0.06 -0.10 to 0.002 0.18
Lean mass index (kg/m2) 0.37 0.024 to 0.040 <0.0001
Adjusted R2 0.16
Women (n = 291)
Age (years) 0.15 0.000 to 0.005 0.034
Lean mass index (kg/m2) 0.11 0.000 to 0.027 0.051
S-glucose (mmol/L) 0.17 0.014 to 0.113 0.01
S-HbA1c (%) 0.04 -0.063 to 0.120 0.54
S-total-cholesterol (mmol/L) 0.06 -0.130 to 0.40 0.31
Adjusted R2 0.09
ALT: alanine transaminase. ∗Analyzed log-transformed. ∗∗Values are
regression coefficients (95% CI) expressed in ALT U/L for a 1-unit change
in independent variables.
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population-based study [48]. Further, a link between ALT
and muscular glucose uptake was found in women only,
which may hypothetically explain why ALT appears to play
a different role as a CVD risk marker in men and women
[49]. In parallel, ALT correlated with metabolic variables
(glucose, HbA1C, and cholesterol) in women but not in
men in the present study. In a large Italian study, ALT
associated positively with BMI, glucose, cholesterol, and tri-
glycerides and increased with younger age groups (until third
decade in males and fifth decade in females) but decreased in
older age groups [50]. Consequently, gender should be taken
into account when planning clinical ALT studies.
4.1. Strengths and Shortcomings. Although the risk of statisti-
cal type 2 error is higher in secondary research studies due to
uncertain sample size and invalid selection criteria, the larger
female subgroup provides evidence to support the findings of
gender differences in this study. BMI do not distinguish
between fat and muscle content, nor does it reflect body fat
distribution. These characteristics may impair the validity
of BMI as an obesity marker and argue for the use of DEXA
in such studies [51, 52]. Similarly, people with sarcopenic
phenotype, i.e., those with increased adipose tissue and
reduced muscle mass, may be overlooked by BMI [52].
Physical activity score did not alter the results here but is a
potential confounder to consider in such studies [18, 53]. A
drawback to the study is lack of information about alcohol
consumption since ALT and AST are not sensitive alcohol
markers [54].
5. Conclusion
ALT was positively associated with body lean mass in men
and women but associated with fat mass only in men in this
obese population. These findings suggest that the ALT-
obesity relationship may partly be explained by different
gender biology. Whether lean mass is more important than
fat mass to explain how ALT relates to obesity needs to be
confirmed and further investigated.
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